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For more than two decades, bupropion has been clinically prescribed for the
treatment of depression (Wellbutrin), and more recently for smoking cessa-
tion (Zyban). Bupropion is conventionally described as a dual norepinephrine
dopamine reuptake inhibitor, therefore effective as an antidepressant. However,
we and others have shown that it also interacts with receptors of the Cys-loop
superfamily, namely neuronal nicotinic acetylcholine receptors. In the contin-
uum of exploring the molecular interactions of bupropion with other prominent
members of the Cys-loop superfamily, we report here that bupropion addition-
ally inhibits 5-hydroxytryptamine (serotonin) type 3A receptors (5-HT3ARs).
5-HT3ARs are cation-conducting, homo-pentameric ligand-gated ion channels
of the Cys-loop superfamily which are structurally and functionally distinct
from other serotonin receptors that are G-proteins. 5-HT3 receptors are cur-
rent targets for anti-emetics mainly used in cancer chemotherapy, as well as
potential future targets for disorders including anxiety, schizophrenia, and
Alzheimer’s disease.
Here we characterized our newly-identified interaction of bupropion with 5-
HT3ARs with electrophysiological and radioligand binding studies. In oocytes,
bupropion inhibited 5-HT3AR-mediated currents with an IC50 value of 87 mM
(nH ¼ 1.2). That 300 mM bupropion inhibited [3H]-5-HT or [3H]-granisetron
(a competitive antagonist) binding by ~ 20% indicated at best weak interaction
with the agonist binding site. In contrast, the effect of different concentrations
of bupropion on serotonin concentration-response curves suggested a non-
competitive nature of interaction. Along these lines, importantly, the inhibition
of serotonin-evoked currents recorded from oocytes was proportional to the
length of preincubation time with bupropion.
In summary, our results are indicative of a negative allosteric interaction of
bupropion with the 5-HT3AR. Currently, experiments are underway to identify
the site(s) of interaction for bupropion within the 5- HT3AR.
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Pentameric ligand-gate ion channels (pLGIC) such as the GABAA-, 5-HT3-
and Glycine receptor play a crucial role in neurotransmission and are targeted
by a wide variety of drugs including anesthetics, benzodiazepines, and anticon-
vulsants. Despite their high pharmacological importance, little is known about
the pathway from neurotransmitter binding in the extracellular domain to the
opening of the channel in the transmembrane domain. Partly, this is due to
the lack of high-resolution structural data of pharmacologically relevant
receptors. Recently however, the crystallographic structures of the C. elagans
glutamate-gated chloride channel (GluCl) both in an apo- as well as in a pre-
sumed open state became available (PDB: 4TNV, 4TNW; 3RHW). Based on
theses structures along with observations made from molecular dynamics sim-
ulations, we focused our interest on one specific loop in the extracellular
domain. We have used electrophysiological experiments on Xenopus oocytes
to explore the effect of mutations in loop F on the activation of GluCl by
glutamate. We also investigated the influence of the partial allosteric agonist
ivermectin on glutamate response both in presence and absence of the same
mutations in loop F. We found that mutation of a residue in this region has a
significant influence on glutamate response. This suggests that this region plays
an important role in the pathway between ligand binding to channel opening.
These insights should help to better understand the underlying mechanism of
this receptor family and might open up new possibilities for drug treatment.
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Texas Tech University Health Sciences Center, Lubbock, TX, USA.Bupropion is one of the most common drugs prescribed for treating depression
and aiding smoking cessation, and is generally well tolerated with the exception
of a rare dose-dependent incidence of seizures. It inhibits norepinephrine
and dopamine reuptake, as well as noncompetitively antagonizes neuronal
nicotinic acetylcholine receptors, which are members of the Cys-loop super-
family. While investigating its effects on other key members of this superfam-
ily, bupropion showed complex modulation of the g-aminobutyric acid type A
(GABAA) a1b2g2 receptor function.
In the brain, GABAA a1b2g2 receptors are one of the most abundant chloride-
conducting hetero-pentameric ligand-gated ion channels. They are targets for a
number of drugs including anesthetics, anticonvulsants, anxiolytics, hypnotics,
and muscle relaxants.
To the best of our knowledge, the interaction of bupropion with the GABAA
receptor has not yet been described. Therefore, the primary goal of this study
was to characterize the functional interactions of bupropion with the GABAA
a1b2g2 receptor. In oocytes, bupropion-alone (0.1 mM - 3 mM) directly
activated GABAA receptor-mediated currents. The comparison of dose-
response curves showed that bupropion-activation was lower in potency
(EC50¼1.5 mM vs. 1.3 mM) and efficacy (49.5% vs. 100%) than that for
GABA, consistent with partial agonism of the GABAA receptor. Interestingly,
at lower concentrations (0.001 mM - 100 mM) bupropion inhibited 0.5 mM
GABA-induced currents by ~ 8 - 20%; in contrast, at higher concentrations
(1 mM - 3 mM) it potentiated GABA-induced currents by ~ 50 - 70%. Notably,
in many ways bupropion mimics the actions of some of the general anesthetics
(e.g. propofol) at the GABAA receptor. This warrants exploring the bupropion
binding site(s) within these receptors.
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GABA is the predominant mediator of inhibitory neurotransmission in the
brain, and upon release rapidly activates ionotropic GABAARs. These receptors
are members of the pentameric ligand gated ion channel (pLGIC) family and
are the targets of a range of clinical and endogenous allosteric modulators,
including general anesthetics, alcohols and neurosteroids. Many of these
compounds bind in the transmembrane domain (TMD) of GABAARs and selec-
tively potentiate or inhibit activity, and in some cases directly gate the channel.
A number of crystal structures of prokaryotic and eukaryotic pLGICs have now
been solved, including the first GABAAR structure, the human b3 homopen-
tamer. However, high resolution structures that reveal the molecular basis
for allosteric modulation of GABAARs are currently unavailable. Here we
report the construction, characterization and crystallization of a chimeric
pLGIC, which is amenable to structural studies of GABAAR transmembrane
pharmacology.
We have generated a chimeric receptor of the extracellular segment from the
proton-gated ion channel from Gloeobacter violaceus (GLIC) and the trans-
membrane segment of the anion-selective human a1 GABAA receptor. The
GLIC-a1 chimera formed functional proton-gated channels when expressed
in Xenopus oocytes. Proton gated currents of the chimeric channel were poten-
tiated by positive modulatory neurosteroids and depressed by inhibitory neuro-
steroids, whilst GLIC is normally insensitive to these compounds. This receptor
can be overexpressed in insect cells and used to generate purified and intact ho-
mopentameric receptor (as determined by native mass spectrometry). Further-
more the purified protein can be used to grow protein crystals under a range of
conditions. We are currently carrying out crystallization trials to generate
diffraction quality crystals of our chimera for structural determinations.
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Dopamine is a critical neuromodulator that governs movement and motivation.
Although dopamine is only thought to target GPCRs in vertebrates (D1-5), it
can activate a Cys-loop pentameric ligand-gated ion channel in C. elegans
(LGC-53). This channel shares homology with mammalian GABAA receptors,
among other Cys-loop channels. The GABAA b3 subunit in particular is impor-
tant for mediating tonic GABA signaling in dopamine-projecting striatal me-
dium spiny neurons. We found 30% residue identity between ligand-binding
domains of LGC-53 and b3, and hypothesized that b3-containing GABAA
receptors may be directly modulated by DA. To address this, we used
immunolabeling with specific anti-b3 antibodies and whole-cell patch clamp
